

## AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

### Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/0051	
Drug name and formulations:	Spiolto® Respimat® 2.5mcg/2.5mcg	
Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	No additional concerns beyond existing products.
Clinical effectiveness	<i>Established licensed product</i>	Evidence that it is useful for patients with low inspiratory capacity and the only LAMA/LABA available as a mist.
Strength of evidence		Moderate
Cost effectiveness or resource impact	£	Cost neutral. Identical price to the other LAMA/LABA combinations.
Place of therapy relative to available treatments	<i>1/2<sup>nd</sup> tier</i>	In line with other LAMA/LABA options, treatment pathway outlined in COPD guidelines.
National guidance and priorities	<i>NICE, MTRAC</i>	Consistent with the Global Initiative for Obstructive Lung Disease (GOLD) guidelines updated in 2017, and the NICE COPD Clinical Guideline, although this has not been updated recently and does not include the LAMA/LABA combinations
Local health priorities	<i>CCG views</i>	CCGs supportive.
Equity of access	<i>Equality assessment</i>	N/A
Stakeholder views	<i>Define wider groups to be engaged</i>	N/A
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	N/A

### Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	GREEN
Implementation requirements:	
Implementation monitoring:	